Restasis Multidose

Heymann Nephritis, Lupus Nephritis, Nephrotic Syndrome + 30 more
Treatment
27 FDA approvals
20 Active Studies for Restasis Multidose

What is Restasis Multidose

CyclosporineThe Generic name of this drug
Treatment SummaryCyclosporine is a medication used to prevent organ rejection in transplant patients and treat certain autoimmune and inflammatory conditions. It is derived from a fungus called _Beauveria nivea_ and was first introduced in 1983 by the pharmaceutical company Sandoz (now Novartis).
Sandimmuneis the brand name
image of different drug pills on a surface
Restasis Multidose Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sandimmune
Cyclosporine
1983
68

Approved as Treatment by the FDA

Cyclosporine, also known as Sandimmune, is approved by the FDA for 27 uses which include Therapeutic immunosuppression and Prophylaxis against graft versus host disease .
Therapeutic immunosuppression
Prophylaxis against graft versus host disease
Chronic Graft Versus Host Disease
Liver
Glomerulosclerosis, Focal Segmental
Helps manage Focal Segmental Glomerulosclerosis (FSGS)
Heart Transplant Rejection
Heymann Nephritis
Helps manage Glomerulonephritis, Membranous
Focal Segmental Glomerulosclerosis (FSGS)
Helps manage Focal Segmental Glomerulosclerosis (FSGS)
Liver Transplant Rejection
Prophylaxis against heart transplant rejection
severe, active Rheumatoid arthritis
Helps manage severe, active Rheumatoid arthritis
Patients who do not adequately respond to methotrexate alone
Used to treat Patients who do not adequately respond to methotrexate alone in combination with Methotrexate
Kidney Transplant Rejection
Steroid Resistant Nephrotic Syndrome
Helps manage Steroid Resistant Nephrotic Syndrome
Steroid Dependent Nephrotic Syndrome
Helps manage Steroid Dependent Nephrotic Syndrome
Glomerulosclerosis
Helps manage Glomerulosclerosis
severe, recalcitrant Plaque psoriasis
Helps manage severe, recalcitrant Plaque psoriasis
Not responsive to other therapy
Helps manage Not responsive to other therapy
Bone Marrow Transplantation
Prophylaxis against stem cell transplant rejection
Transplantation
Rheumatoid Arthritis
Helps manage severe, active Rheumatoid arthritis
Nephrotic Syndrome
Helps manage Nephrotic Syndrome
Bone Marrow
Kidney Transplantation
Nephrotic Syndrome
Helps manage Steroid Resistant Nephrotic Syndrome
Nephrotic Syndrome
Helps manage Steroid Dependent Nephrotic Syndrome

Effectiveness

How Restasis Multidose Affects PatientsCyclosporine helps to stop or reduce the effects of serious immune system reactions, such as after an organ transplant or bone marrow transplant. Common side effects include excessive hair growth, swollen gums, and high cholesterol levels. There is some concern that taking this drug may damage the kidneys.
How Restasis Multidose works in the bodyCyclosporine works by preventing T cells from becoming active and causing inflammation. It does this by preventing a certain receptor from binding to a protein called calcineurin, which helps activate T cells. This stops the production of cytokines, which are molecules that cause inflammation. It also lowers the levels of other molecules involved in T cell function and development.

When to interrupt dosage

The prescribed quantity of Restasis Multidose is dependent on the diagnosed circumstance, such as Interstitial Cystitis, Focal Segmental Glomerulosclerosis (FSGS) and Excessive tearing. The dose is contingent upon the modality of administration (e.g. Liquid - Intravenous or Ophthalmic; Topical) presented in the table below.
Condition
Dosage
Administration
Organ Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Prophylaxis against stem cell transplant rejection
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Bone Marrow
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Conjunctivitis, Allergic
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Patients who do not adequately respond to methotrexate alone
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Not responsive to other therapy
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Heymann Nephritis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Rosacea
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Ulcerative Colitis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Juvenile arthritis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Cystitis, Interstitial
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Disease
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Bone Marrow Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Chronic Graft Versus Host Disease
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Dry Eye Syndromes
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Therapeutic immunosuppression
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical

Warnings

Restasis Multidose Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Psoriasis
Do Not Combine
Abnormal Renal Function
Do Not Combine
Hypertensive disease
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Cyclosporine may interact with Pulse Frequency
There are 20 known major drug interactions with Restasis Multidose.
Common Restasis Multidose Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Cyclosporine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Cyclosporine.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Cyclosporine.
Aliskiren
Major
The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Cyclosporine.
Restasis Multidose Toxicity & Overdose RiskThe toxic dose of cyclosporine in rats is 1480mg/kg, and the lowest toxic dose in humans is 12mg/kg. If someone takes too much cyclosporine, it is recommended to induce vomiting and perform a stomach lavage within 2 hours. There is not much information available about the effects of cyclosporine overdose, but it can lead to liver and kidney damage. In one case, a 26 year old woman experienced nausea, flushing, tremor, vertigo, and vomiting which resolved within 1 day. Anorexia and feeling of increased body girth were also reported and resolved within 2
image of a doctor in a lab doing drug, clinical research

Restasis Multidose Novel Uses: Which Conditions Have a Clinical Trial Featuring Restasis Multidose?

81 active trials are studying the potential of Restasis Multidose to provide therapeutic benefits for patients with Chronic Graft Versus Host Disease, Kidney Diseases and Ulcerative Colitis.
Condition
Clinical Trials
Trial Phases
Therapeutic immunosuppression
0 Actively Recruiting
Rheumatoid Arthritis
0 Actively Recruiting
Bone Marrow
1 Actively Recruiting
Early Phase 1
severe, recalcitrant Plaque psoriasis
0 Actively Recruiting
Nephrotic Syndrome
5 Actively Recruiting
Phase 2, Not Applicable, Phase 3
Disease
0 Actively Recruiting
Prophylaxis against graft versus host disease
0 Actively Recruiting
Liver
0 Actively Recruiting
Heymann Nephritis
3 Actively Recruiting
Phase 2, Phase 1
Glomerulosclerosis
0 Actively Recruiting
Prophylaxis against heart transplant rejection
0 Actively Recruiting
Organ Transplantation
0 Actively Recruiting
Excessive tearing
0 Actively Recruiting
Transplantation
0 Actively Recruiting
Lupus Nephritis
24 Actively Recruiting
Phase 3, Phase 2, Phase 1, Phase 4
Not responsive to other therapy
0 Actively Recruiting
Kidney Transplantation
0 Actively Recruiting
Glomerulosclerosis, Focal Segmental
10 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 1, Phase 4
Uveitis
3 Actively Recruiting
Not Applicable, Phase 3
Nephrotic Syndrome
0 Actively Recruiting

Restasis Multidose Reviews: What are patients saying about Restasis Multidose?

3.3Patient Review
6/30/2018
Restasis Multidose for Dry Eye
The Restasis multidose dispenser bottle is not user-friendly. Too difficult to squeeze, and drops are wasted on the bottle nipple. I went back to single dose - which was easier to use and lasted much longer.
3.3Patient Review
6/30/2018
Restasis Multidose for Dry Eye
The Restasis multidose dispenser bottle was not easy to use. I ended up wasting a lot of medication because it was difficult to control the amount of drops that came out.
3Patient Review
7/2/2022
Restasis Multidose for Dry Eye
I wasn't thrilled with the design of the bottle. It seems like it would be easy to waste product. I'm going to try a generic brand next time.
3Patient Review
7/2/2022
Restasis Multidose for Dry Eye
The multi-use bottle is very poorly designed. A cynical person might say that it was designed to waste product. I am going to try the generic cyclosporine.
2.7Patient Review
2/26/2022
Restasis Multidose for Dry Eye
I've been using Restasis for years with the single-dose vials and never had a problem. The new multi-dose bottle is terrible. You have to squeeze it so hard to get anything to come out, and then more than one drop comes out. I can already tell this bottle won't last thirty days. They need to fix this!
2.7Patient Review
2/26/2022
Restasis Multidose for Dry Eye
I've been using Restasis for years with the single-dose vials, and I never had a problem. The new multi-dose bottle is terrible. You have to squeeze it so hard to get anything to come out, and then more than one drop comes out. I can already tell this bottle won't last thirty days. They need to fix this!
2.7Patient Review
4/2/2022
Restasis Multidose for Dry Eye
The drops are hard to dispense and the bottle doesn’t last but 20 days. This is very expensive for such a short amount of time, and I won't be buying it again.
2.7Patient Review
4/2/2022
Restasis Multidose for Dry Eye
The drops are hard to dispense and the bottle doesn’t last but 20 days, which is very expensive. Will not buy again.
2Patient Review
8/9/2018
Restasis Multidose for Dry Eye
The single-use doses of this medication were great, but I ran into issues when trying to use the bottle. The amount in each bottle never lasted long enough, and I often went weeks without any relief. Additionally, the price per month skyrockets if you need to use the individual vials rather than the bottles. Suffering from dry eyes is no fun, especially when you don't have access to your needed medication!
2Patient Review
8/9/2018
Restasis Multidose for Dry Eye
The single-use doses were great, but when I moved to the bottle usage, it was awful. I never had enough drops, and would go weeks without any relief. The program is terrible - it only offers $5 if you use the bottles, and then goes up to $30 per month for the individual vials that work out in giving a 30 day supply as needed. I'm very unhappy and will be contacting my doctor to see if there is a different medication I can use. Suffering is not fun, especially when all you need is some eye drop relief!
1.7Patient Review
10/2/2022
Restasis Multidose for Drying and Inflammation of Cornea and Conjunctiva of Eyes
The multi-dose container is very difficult to use, even for nurses with years of experience. I'm only supposed to use one drop in each eye, but it's impossible to control the amount that comes out. As a result, I go through this medication much faster than I should.
1.7Patient Review
6/19/2021
Restasis Multidose for Dry Eye
The multi-dose version of this medication was very difficult to use and only lasted me 20 days, even though it is supposed to be a 30 day supply. In addition, it did not help at all with my dry eye problem. I'm considering trying the single vial next, even though it's more expensive.
1.7Patient Review
10/2/2022
Restasis Multidose for Drying and Inflammation of Cornea and Conjunctiva of Eyes
I completely agree with the other negative reviews about how hard it is to get the right amount of medication out of the container. Even for a nurse with steady hands, it's impossible to use as directed. This product is clearly designed to make more money off of customers by not lasting very long.
1.7Patient Review
6/19/2021
Restasis Multidose for Dry Eye
I found the multi-dose version to be very difficult to use, and it only lasted me 20 days instead of the 30 it was supposed to. Plus, it did nothing to help my dry eyes. I'm considering switching to the single-vial option, even though it's more expensive.
1.7Patient Review
8/30/2022
Restasis Multidose for Dry Eye
The container design is really poor. You have to squeeze too hard for the product to come out, and then way too much comes out! Additionally, it's very difficult to get the product in my eyes. Awful!!
1.7Patient Review
8/30/2022
Restasis Multidose for Dry Eye
The multi-use container is a joke. You have to squeeze really hard for anything to come out and then way too much comes out AND it’s impossible to get it right in my eyes. Awful!!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about restasis multidose

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much does Restasis MultiDose cost?

"The price of RESTASIS and RESTASIS MultiDose is $645.63 per month, plus any additional pharmacy charges depending on where you purchase your medicine."

Answered by AI

Is Restasis MultiDose available?

"RESTASIS is a medication that is FDA-approved to help patients with Chronic Dry eye produce more of their own tears. RESTASIS MultiDose is a preservative-free medication that is FDA-approved and available in a multidose bottle."

Answered by AI

How many drops are in a Restasis MultiDose bottle?

"A bottle of Restasis MultiDose contains approximately 120 doses or drops. The recommended dosage is one drop into each eye twice daily. This means that one bottle should last a little over 30 days."

Answered by AI

What is the difference between Restasis and Restasis MultiDose?

"The preservative-free formulation of RESTASIS that doctors have prescribed 6.4 million times since 2003 is available in a patented bottle design. Compared to the single-use vials of RESTASIS, the MultiDose version is more compact, uses less plastic in packaging, and is the same price."

Answered by AI

Clinical Trials for Restasis Multidose

Image of Nephrology Consultants, LLC in Huntsville, United States.

BI 764198 for Focal Segmental Glomerulosclerosis

Any Age
All Sexes
Huntsville, AL
This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS. Participants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine. Participants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS. Participants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Phase 3
Waitlist Available
Nephrology Consultants, LLC (+19 Sites)Boehringer Ingelheim
Image of Washington University School of Medicine in St Louis, United States.

Pain Mechanisms for Juvenile Arthritis

9 - 17
All Sexes
St Louis, MO
Juvenile idiopathic arthritis (JIA) is the most common rheumatologic disease in children. The main symptoms of JIA, which are often the primary focus of treatment, include joint swelling, stiffness, and tenderness. Additional symptoms can include malaise, fatigue, and pain. However, the exact mechanisms contributing to pain are not yet fully understood. Participants will complete a 2.5-hours study session. In the study session, psychophysical assessments of thermal and pressure stimuli will be performed. In addition, demographic, social, pubertal maturation, and behavioral and psychological factors will be collected via questionnaires. A saliva sample and/or blood draw may occur for the analysis of various immune factors and sex hormones. If a joint aspiration is done as part of their standard of care, we will request a sample of the synovial fluid for analyses of immune, hormonal and/or genetic factors. Participants will have the option to participate in additional optional follow-up study visits (every 3 months, up to 1 year) and to complete monthly surveys asking about their juvenile arthritis.
Recruiting
Has No Placebo
Washington University School of MedicineHadas Nahman-Averbuch, PhD
Have you considered Restasis Multidose clinical trials? We made a collection of clinical trials featuring Restasis Multidose, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

Emapalumab for Graft-versus-Host Disease

18 - 75
All Sexes
Duarte, CA
This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced-intensity donor (allogeneic) hematopoietic cell transplant (HCT). Giving chemotherapy, such as fludarabine, melphalan, or busulfan, before a donor \[peripheral blood stem cell\] transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When healthy stem cells for a donor are infused into a patient (allogeneic HCT), they may help the patient's bone marrow make more healthy cells and platelets. Allogeneic HCT is an established treatment, however, GVHD continues to be a major problem of allogeneic HCT that can complicate therapy. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Emapalumab binds to an immune system protein called interferon gamma. This may help lower the body's immune response and reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Mycophenolate mofetil is a drug used to prevent GVHD after organ transplants. It is also being studied in the prevention of GVHD after stem cell transplants for cancer, and in the treatment of some autoimmune disorders. Mycophenolate mofetil is a type of immunosuppressive agent. Giving emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil may be safe, tolerable and/or effective in preventing GVHD in patients with AML or MDS after a reduced-intensity allogeneic HCT.
Phase 1
Waitlist Available
City of Hope Medical CenterAmandeep Salhotra
Have you considered Restasis Multidose clinical trials? We made a collection of clinical trials featuring Restasis Multidose, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

Vedolizumab + Cyclophosphamide + Tacrolimus for Graft-versus-Host Disease

18 - 80
All Sexes
Duarte, CA
This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced intensity conditioning. Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a donor. Giving reduced conditioning chemotherapy before an allogeneic HCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new stem cells to grow using less than standard doses of chemotherapy. Sometimes, the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Vedolizumab is a monoclonal antibody, which is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). It may reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus suppresses the immune system by preventing the activation of certain types of immune cells. Giving vedolizumab plus PTCy and short course tacrolimus may be effective at preventing GVHD after allogeneic HCT.
Phase 2
Recruiting
City of Hope Medical CenterMonzr M. Al Malki
Image of National Institutes of Health Clinical Center in Bethesda, United States.

ManNAc for FSGS

18 - 115
All Sexes
Bethesda, MD
Background: Focal segmental glomerulosclerosis (FSGS) is a disease that causes scarring in parts of the kidneys that filter waste. This can lead to protein loss in the urine, which can worsen kidney function. The kidneys may fail over time, and dialysis or a kidney transplant may be needed. Other treatments for this disease do not always work and often have adverse effects. Better treatments for FSGS are needed. Objective: To test a study drug (ManNAc) in people with FSGS. Eligibility: People aged 18 years and older with FSGS. Design: Participants will have 5 to 6 clinic visits over 14 weeks. Two of the visits will require overnight stays for 2 or 3 nights. ManNAc is a white powder that comes in a sachet. It is dissolved in water and taken twice a day by mouth. Participants will take their first dose at the clinic. They will learn how to store ManNAc and prepare each dose. They will record their doses in a diary. They will also write down any adverse effects or troubles they have using the drug at home. During clinic visits, participants will have physical exams with blood and urine tests. They will complete questionnaires about their health, sleep habits, and fatigue symptoms. During overnight visits, participants will also have 24-hour urine collection. A study team member will call participants 1 week after the first dose to check on their health. Follow-up phone calls will then be every 2 weeks after each clinic visit. Participants may meet with a dietitian to discuss nutrition while taking the ManNAc. Participants may choose to have genetic tests.
Phase 2
Recruiting
National Institutes of Health Clinical CenterWilliam A Gahl, M.D.
Have you considered Restasis Multidose clinical trials? We made a collection of clinical trials featuring Restasis Multidose, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security